Meusinvest is a venture capital fund specializing in the biotech and health tech sectors. They focus on early-stage companies, primarily through Series A investments, with funding ranging from $250,000 to $5 million. A notable investment is Amyl Therapeutics. With over 20 years of experience, Meusinvest has become a key player in Liège's financial landscape, supporting 450 small and medium-sized enterprises and regional projects.
